Treatment of Mammary Carcinomas in HER-2 Transgenic Mice through Combination of Genetic Vaccine and an Agonist of Toll-Like Receptor 9, Clinical Cancer Research, vol.15, issue.5, pp.1575-84, 2009. ,
DOI : 10.1158/1078-0432.CCR-08-2628
Structure of the extracellular region of ERBB3 reveals an interdomain tether, Science, vol.209, pp.1330-1333, 2002. ,
Receptor tyrosine kinases and their activation in melanoma, Pigment Cell & Melanoma Research, vol.106, issue.3, pp.446-61, 2011. ,
DOI : 10.1111/j.1755-148X.2011.00836.x
ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839), Melanoma Research, vol.19, issue.3, pp.156-66, 2009. ,
DOI : 10.1097/CMR.0b013e32832c6339
HER3 Is a Determinant for Poor Prognosis in Melanoma, Clinical Cancer Research, vol.14, issue.16, pp.5188-97, 2008. ,
DOI : 10.1158/1078-0432.CCR-08-0186
The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing, The EMBO Journal, vol.18, issue.12, pp.3348-58, 1999. ,
DOI : 10.1093/emboj/18.12.3348
Neuregulin-Induced ErbB3 Downregulation Is Mediated by a Protein Stability Cascade Involving the E3 Ubiquitin Ligase Nrdp1, Molecular and Cellular Biology, vol.27, issue.6, 2007. ,
DOI : 10.1128/MCB.01245-06
Interaction of antibodies with ErbB receptor extracellular regions, Experimental Cell Research, vol.315, issue.4, pp.659-70, 2009. ,
DOI : 10.1016/j.yexcr.2008.10.008
Mechanism of Action of Anti-Her2 Monoclonal Antibodies: Scientific Update on Trastuzumab and 2c4, Adv Exp Med Biol, vol.532, pp.253-68978, 2003. ,
DOI : 10.1007/978-1-4615-0081-0_21
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex, Cancer Cell, vol.5, issue.4, pp.317-345, 2004. ,
DOI : 10.1016/S1535-6108(04)00083-2
Cannibalism of Live Lymphocytes by Human Metastatic but Not Primary Melanoma Cells, Cancer Research, vol.66, issue.7, pp.3629-3667, 2006. ,
DOI : 10.1158/0008-5472.CAN-05-3204
Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis, Oncogene, vol.26, issue.6, 2011. ,
DOI : 10.1038/onc.2011.275
ErbB receptors mediate both migratory and proliferative activities in human melanocytes and melanoma cells, Melanoma Research, vol.15, issue.1, pp.21-29, 2005. ,
DOI : 10.1097/00008390-200502000-00005
The RTK/RAS/BRAF/PI3K Pathways in Melanoma: Biology, Small Molecule Inhibitors, and Potential Applications, Seminars in Oncology, vol.34, issue.6, pp.546-54, 2007. ,
DOI : 10.1053/j.seminoncol.2007.09.011
NRG1???/???ERBB3 signaling in melanocyte development and melanoma: inhibition of differentiation and promotion of proliferation, Pigment Cell & Melanoma Research, vol.57, issue.Pt 3, pp.773-84, 2009. ,
DOI : 10.1111/j.1755-148X.2009.00616.x
Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor-PI3K Axis, Science Signaling, vol.2, issue.77, p.31, 2009. ,
DOI : 10.1126/scisignal.2000352
An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation, Cancer Research, vol.70, issue.6, pp.2485-94, 2010. ,
DOI : 10.1158/0008-5472.CAN-09-3145
A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies, Cancer Cell, vol.20, issue.4, pp.472-86, 2011. ,
DOI : 10.1016/j.ccr.2011.09.003
Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors, Journal of Cellular Physiology, vol.104, issue.10, 2011. ,
DOI : 10.1002/jcp.24037
Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling, Proceedings of the National Academy of Sciences, vol.107, issue.30, pp.13252-13259, 2010. ,
DOI : 10.1073/pnas.0913476107
Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: Implications for cancer immunotherapy, Proceedings of the National Academy of Sciences, vol.102, issue.6, pp.1915-1935, 2005. ,
DOI : 10.1073/pnas.0409610102
Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis, Proceedings of the National Academy of Sciences, vol.106, issue.9, pp.3294-3303, 2009. ,
DOI : 10.1073/pnas.0812059106
Endocytosis and intracellular trafficking of ErbBs, Experimental Cell Research, vol.315, issue.4, pp.3093-10618793634, 2008. ,
DOI : 10.1016/j.yexcr.2008.07.029
The melanoma book, a complete guide to prevention and treatment. Penguin Group: USA, 2005. ,
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.8, pp.711-734, 2010. ,
DOI : 10.1056/NEJMoa1003466
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, New England Journal of Medicine, vol.364, issue.26, pp.2507-2523, 2011. ,
DOI : 10.1056/NEJMoa1103782
Mutant BRAF Melanomas???Dependence and Resistance, Cancer Cell, vol.19, issue.1, 2011. ,
DOI : 10.1016/j.ccr.2011.01.008
URL : http://doi.org/10.1016/j.ccr.2011.01.008
EGFR Signaling and Drug Discovery, Oncology, vol.77, issue.6, pp.400-410, 2009. ,
DOI : 10.1159/000279388
Cell Signaling by Receptor Tyrosine Kinases, Cell, vol.141, issue.7, pp.1117-1151, 2010. ,
DOI : 10.1016/j.cell.2010.06.011
ErbB receptors: from oncogenes to targeted cancer therapies, Journal of Clinical Investigation, vol.117, issue.8, pp.2051-2059, 2007. ,
DOI : 10.1172/JCI32278
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3, Nature Reviews Cancer, vol.25, issue.7, pp.463-75, 2009. ,
DOI : 10.1038/nrc2656
The deaf and the dumb: the biology of ErbB-2 and ErbB-3, Experimental Cell Research, vol.284, issue.1, pp.54-65, 2003. ,
DOI : 10.1016/S0014-4827(02)00101-5
NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancer, The EMBO Journal, vol.19, issue.13, pp.3159-67, 2000. ,
DOI : 10.1093/emboj/19.13.3159
Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas, Oncogene, vol.10, pp.1813-217538656, 1995. ,
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation, Proceedings of the National Academy of Sciences, vol.100, issue.15, pp.8933-8941, 2003. ,
DOI : 10.1073/pnas.1537685100
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling, Science, vol.316, issue.5827, pp.1039-1082, 2007. ,
DOI : 10.1126/science.1141478
Transcriptional and posttranslational upregulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase, Proc Natl Acad Sci, 2011. ,